Characterize infections and outcomes developed in relapsed/refractory multiple myeloma (RRMM) patients treated with Teclistamab (SPOT)

Study type

• Study topic:
  Disease /health condition

  Human medicinal product
• Study type:
  Non-interventional study
• Scope of the study:
  Disease epidemiology

Study drug and medical condition

• Medicinal product name:
  TECVAYLI
• Study drug International non-proprietary name (INN) or common name:
  TECLISTAMAB
• Anatomical Therapeutic Chemical (ATC) code:
  (L01FX24) teclistamab

  teclistamab
• Additional medical condition(s):
  Multiple Myeloma